PRMT5 (MTAP-deleted cancers)
An enzyme that cancers lacking the MTAP gene (about 10-15% of all tumours) depend on more than normal cells do; new inhibitors designed to exploit that difference are in late trials. This dossier gathers the 0 products (0 approved), 0 trials, 1 pathway and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Type II protein arginine methyltransferase forming symmetric dimethylarginine on histones (H4R3, H3R8) and splicing factors (SmD3); essential for spliceosome function; MTA is a competitive SAM-site inhibitor accumulating when MTAP is lost.
- Mesothelioma (~40% MTAP deletion)
- Glioblastoma (~40%)
- Pancreatic adenocarcinoma (~20%)
- Urothelial carcinoma (~20%)
- NSCLC (~15%)
- Cholangiocarcinoma, melanoma, sarcoma (subsets)
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Mesothelioma | 40% | MTAP homozygous deletion | ||
| Glioma & glioblastoma | 40% | MTAP deletion | ||
| Pancreatic ductal adenocarcinoma | 20% | MTAP deletion | ||
| Non-small-cell lung cancer | 15% | MTAP deletion |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →- Synthetic lethality: paired dependenciesNode: → PRMT5, MAT2A · 7 druggable nodes
Two genes are synthetically lethal when losing either alone is fine but losing both kills the cell. Cancers that have already lost one (a tumour suppressor you cannot put back) become uniquely dependent on the other, which you can drug. BRCA and PARP was the first proof; a dozen more pairs are now in trials.
Which nodes have drugs →
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Key papers and the live literature
Preprints →Query for this target: (TITLE:"PRMT5" OR ABSTRACT:"PRMT5" OR TITLE:"MTAP-deleted cancers" OR ABSTRACT:"MTAP-deleted cancers") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRMT5 (MTAP-deleted cancers), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/prmt5-mtap.json. Licence CC BY 4.0.